-
Mashup Score: 3What Major Themes Define Recent Lower-Risk MDS Prognostication, Treatment? | Blood Cancers Today - 19 day(s) ago
Jamile Shammo, MD, leads a roundtable discussion on the effect of molecular data incorporation and goals in treatment.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 3Health Care Resource Utilization: Luspatercept vs ESAs in MDS - 21 day(s) ago
Saeed Sadeghi, MD, discusses the impact of health care resource utilization on treatment decisions and quality of life for patients with myelodysplastic syndromes (MDS), highlighting real-world data presented at SOHO that compares the resource utilization of U.S. patients treated with luspatercept versus erythropoiesis-stimulating agents (ESAs).
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
WATCH: Saeed Sadeghi, MD, (@SaeedokMD) discusses the impact of health care resource utilization on treatment decisions and quality of life for patients with #MDS. https://t.co/XwqUNjv3PL
-
-
Mashup Score: 2
Sergio A. Giralt, MD, discusses what the most commonly used conditioning regimens for patients with myelodysplastic syndrome undergoing transplants are.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
WATCH: Sergio A. Giralt, MD, discusses what the most commonly used conditioning regimens for patients with #MDS undergoing transplants are. @MSKCancerCenter @SocietyofHemOnc https://t.co/rzvkas9FA6
-
-
Mashup Score: 4The HemOnc Pulse Live: MDS | Blood Cancers Today - 28 day(s) ago
Review exclusive coverage of the MDS-focused discussions and insights from The HemOnc Pulse Live, May 3-4, 2024, in Chicago.
Source: bloodcancerstoday.comCategories: General Medicine News, Onc News and JournalsTweet-
📺 This weekend, catch up on the #MDS roundtable with @Dr_AmerZeidan, @MdSwoboda, Jamie Koprivnikar, and @drsangeetmd! 💬 The panel talks luspatercept, ESAs, risk stratification, classification systems, and more. ➡️ https://t.co/puFtFcliD8 https://t.co/Ba7OCqcKdk
-
-
Mashup Score: 3The Impact of Luspatercept Versus ESAs on Cytopenias in Lower-Risk MDS | Blood Cancers Today - 1 month(s) ago
Luspatercept yielded greater rates of improvement in cell lineages for patients with transfusion-dependent MDS.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
📝 COMMANDS data: compared with epoetin alfa, luspatercept yielded greater rates of improvement in cytopenias for ESA-naïve patients with transfusion-dependent, lower-risk #MDS. @Santin13Valeria @Dr_AmerZeidan @Ramikomrokji @UwePlatzbecker ➡️ https://t.co/QOxUHH5z09 https://t.co/YguYh2mcZL
-
-
Mashup Score: 1Jamile Shammo, MD, Describes the Impact of NGS Data on MDS Care | Blood Cancers Today - 1 month(s) ago
Dr. Shammo gives her impressions of how growing incorporation of MDS molecular data is changing disease management.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🗨️ “This notion of pre-MDS is becoming prevalent. We used to think about MDS as preleukemia,” said Jamile Shammo, MD, of @NorthwesternMed. 🙌 Check out this interview with Dr. Shammo on the current state of #MDS management. 📺 https://t.co/TYAhz8Hk4e https://t.co/FeO5CXHS1g
-
-
Mashup Score: 1COMMANDS Study Update: Luspatercept vs. Epoetin Alfa in 1L Treatment - 1 month(s) ago
Saeed Sadeghi, MD, discusses the updated data from the COMMANDS study presented at ASCO 2024, emphasizing the significance of outcome data comparing luspatercept to epoetin alfa in first-line (1L) treatment for lower-risk myelodysplastic syndromes (LR-MDS).
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
WATCH: Saeed Sadeghi, MD, discusses the updated data from the COMMANDS study, emphasizing the significance of outcome data comparing luspatercept to epoetin alfa in first-line treatment for lower-risk #MDS. @SaeedokMD https://t.co/r10ho7Kuoc
-
-
Mashup Score: 3How Do Clinicians Navigate the Two MDS Classification Systems? | Blood Cancers Today - 1 month(s) ago
The expert panel describes how having two separate classification systems for MDS affects their clinical practices.
Source: bloodcancerstoday.comCategories: General Medicine News, Oncologists1Tweet-
🎬 In the next episode of this roundtable series, @Dr_AmerZeidan, @MdSwoboda, Jamie Koprivnikar, and @drsangeetmd dive into the two classification systems for #MDS and how it affects their clinical practices. 📺 Watch here! https://t.co/rabi3LxxCp https://t.co/Ql2OrcmKtz
-
-
Mashup Score: 3How Do Clinicians Communicate With Patients About Low-Risk MDS? | Blood Cancers Today - 1 month(s) ago
The expert panel discusses how to explain to patients the range of MDS severities and approach lower-risk disease.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
✨ In this roundtable, moderator @Dr_AmerZeidan and panelists @MdSwoboda, Jamie Koprivnikar, and @drsangeetmd discuss how to explain the range of #MDS severities to patients and how to approach lower-risk disease. ➡️ https://t.co/slx2bF40qM https://t.co/dB4CgiQLCK
-
-
Mashup Score: 4
The expert panel discusses molecular testing’s current place in MDS evaluation and treatment decisions.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🧬 How is molecular testing used in #MDS risk stratification? @Dr_AmerZeidan (@YaleCancer), @MdSwoboda, (@TGHCares), Jamie Koprivnikar (@JTCancerCenter @HMHNewJersey), and @drsangeetmd (@SylvesterCancer) discuss in this roundtable. 📺 https://t.co/Qd3tjri3Xm https://t.co/8WTSozct8g
-
What major themes define recent lower-risk #MDS prognostication treatment? Learn more from this MDS panel with Drs. Jamile Shammo (@NorthwesternU), @MdSwoboda (@TGHCares), Saeed Sadeghi (@dgsomucla) & @benton_leukemia (Rocky Mountain Cancer Centers). ➡️ https://t.co/W69ElFNU3B https://t.co/VBFsnAyZWK